Why is AstraZeneca stock down today?

Traders Union
All News
Financial News
Astrazeneca slides 10.07% today

Highlights

AstraZeneca shares fell sharply after its Wainua drug failed a key Phase III heart trial, erasing £19 billion in market value.
The company halted the HELIOS rare disease study with no material financial impact, while advancing a $2.1 billion licensing deal for a COPD candidate.
The stock trades below major moving averages with sellers in control, likely consolidating between GBX11,074 and GBX13,107 in the near term.

Negative momentum accelerates amid clinical and licensing news

AstraZeneca reported a significant setback when its Wainua drug did not meet its primary objective in a pivotal Phase III heart disease trial, removing £19 billion from its market capitalization and driving additional negative momentum on the FTSE 100. The company also announced that the HELIOS rare disease study was stopped early, with no expected material financial impact. Recent business activity included a $2.1 billion licensing deal with Sino Biopharmaceutical for ex-China rights to a late-stage candidate for chronic obstructive pulmonary disease, and progress towards expanding NHS access to Enhertu, its breast cancer medication developed with Daiichi Sankyo. Officer Mani Sharma was granted ordinary shares under an incentive plan.

Anton Kharitonov, expert at Traders Union, notes AstraZeneca's sharp 10% drop is fueled by failed clinical results and clear technical weakness. He observes that price trades well below all major moving averages, highlighting entrenched bearish sentiment. Kharitonov stresses that conflicting momentum signals and a negative news cycle expose the stock to further downside. He warns that near-term support may not hold if sellers maintain pressure, despite intraday volatility suggesting some buying interest. "With sentiment battered and technical indicators mixed, I see little reason for optimism until there is a shift in either news flow or momentum confirmation," says Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, acknowledges the setback but sees AstraZeneca’s fundamentals remain intact. He highlights positive developments such as the strategic licensing deal and advancing oncology portfolio. Karapetjanc considers market overreaction as common in the wake of drug trial disappointments and expects potential for recovery in coming sessions. "These volatility spikes can create strong accumulation opportunities — I expect AstraZeneca to stabilize and the longer-term bullish structure to reassert itself," says Karapetjanc.

Bearish trends persist as conflicting momentum signals fuel uncertainty

AstraZeneca is trading below its 20-day (GBX13,821), 50-day (GBX13,731), and 200-day (GBX13,768) moving averages, signaling ongoing pressure from sellers across short-, medium-, and long-term trends. Nearest support sits near the GBX12,388 level, with immediate resistance identified at GBX13,107. The longer-term trend confirmation from the MA-50 vs MA-200 alignment remains bearish. Momentum readings are mixed: the MACD signals buy, yet the Average Directional Index (ADX) suggests a sell. Relative Strength Index (RSI) and Commodity Channel Index (CCI) both generate buy signals, while Stochastic RSI recommends a sell. Bull/Bear Power (BBP) indicates buyers currently dominate intraday momentum and also flags overbought conditions. The stock trades at GBX12,806 after slipping GBX1,434 or 10.07% today, opening with a downside gap of roughly 13.01%. Price is mid-range for the day, and intraday volatility stands at 5.81%. The tone remains weak with notable selling pressure following the sharp gap down, and conflicting momentum signals highlight ongoing uncertainty.

Previously it was reported that AstraZeneca's shares faced sustained downside momentum following a major late-stage clinical trial failure and mixed technical signals. The current environment reinforces this bearish backdrop, and with volatility elevated, traders should focus on the GBX13,107 resistance for signs of trend reversal or acceleration of losses if breached.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.